» Articles » PMID: 2261838

Diabetic Cardiomyopathy

Overview
Journal Diabetes Care
Specialty Endocrinology
Date 1990 Nov 1
PMID 2261838
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this article was to review the clinical and experimental features of diabetic cardiomyopathy, with particular relevance to the Black population. One hundred thirty-seven studies were identified, of which 57 were selected as references for this article. Diabetes is associated with the development of cardiomyopathy, independent of coronary atherosclerosis. Pathological studies show myocardial hypertrophy and fibrosis; microvascular pathology is also present, but all of these pathological findings have an uncertain relationship to myocardial failure. Hemodynamic findings of both congestive and restrictive cardiomyopathy have been described. Noninvasive studies revealed abnormal systolic and diastolic function in many diabetic subjects, particularly in the presence of diabetic complications and/or hypertension. Experimental studies have focused on the mildly diabetic dog and the severely diabetic rat. One year of diabetes in dogs resulted in decreased left ventricular compliance and increased interstitial connective tissue. Studies in the diabetic rat showed a marked slowing of contraction and relaxation. Chronic insulin therapy reversed the changes in the rat model. Combining hypertension with diabetes in the rat resulted in increased myocardial and coronary microvascular pathology and greater changes in isolated muscle function, electrophysiology, and contractile protein biochemistry. Many hypertensive diabetic rats died spontaneously, showing signs of congestive heart failure. Diabetic cardiomyopathy is a significant cause of heart failure in diabetic subjects and occurs more frequently in those with microvascular complications and/or hypertension. Clinical studies are needed to clarify the natural history of this disorder, focusing on the benefits of tight control of hyperglycemia and treatment of associated hypertension. Experimental studies will clarify the pathophysiology and contribute to improved therapy. The high prevalence of diabetes and hypertension in Blacks makes these considerations especially relevant to this population.

Citing Articles

Cardiovascular Disease and Diabetes Are Among the Main Underlying Causes of Death in Twenty Healthcare Facilities Across Two Cities in the Democratic Republic of Congo.

Angendu K, Akilimali P, Mwamba D, Komakech A, Magne J Int J Environ Res Public Health. 2024; 21(11).

PMID: 39595717 PMC: 11593621. DOI: 10.3390/ijerph21111450.


Improvement of Cardiac Function and Subcellular Defects Due to Chronic Diabetes upon Treatment with Sarpogrelate.

Tappia P, Elimban V, Shah A, Goyal R, Dhalla N J Cardiovasc Dev Dis. 2024; 11(7).

PMID: 39057635 PMC: 11276782. DOI: 10.3390/jcdd11070215.


Role of CaMKII in diabetes induced vascular injury and its interaction with anti-diabetes therapy.

Chacar S, Abdi A, Almansoori K, Alshamsi J, Al Hageh C, Zalloua P Rev Endocr Metab Disord. 2023; 25(2):369-382.

PMID: 38064002 PMC: 10943158. DOI: 10.1007/s11154-023-09855-9.


Effects of inappropriate cause-of-death certification on mortality from cardiovascular disease and diabetes mellitus in Tonga.

Figueroa C, Linhart C, Dearie C, Fusimalohi L, Kupu S, Morrell S BMC Public Health. 2023; 23(1):2381.

PMID: 38041110 PMC: 10691179. DOI: 10.1186/s12889-023-17294-z.


NOX1 promotes myocardial fibrosis and cardiac dysfunction activating the TLR2/NF-κB pathway in diabetic cardiomyopathy.

Zhang D, Li Y, Wang W, Lang X, Zhang Y, Zhao Q Front Pharmacol. 2022; 13:928762.

PMID: 36225554 PMC: 9549956. DOI: 10.3389/fphar.2022.928762.